A phase I trial of personalized peptide vaccination using long and short peptides in patients with metastatic cancer resistant to standard treatments - New personalized peptide vaccination in patients with metastatic cancer

Kurume University Cancer Vaccine Center0 个研究点目标入组 10 人开始时间: 2014年2月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The following patients must be excluded: 1) Patients who had received pre-therapies including radiotherapy, chemotherapy or immunotherapy within 28 days before the treatment. 2) Patients who had received radiotherapy to the primary cancer lesion except for metastatic lesions within 2 weeks before the treatment. 3) Immunosuppressive treatment using a systematic steroid within the last 12 weeks was not permitted except for using low-dose steroid (less than 20mg as prednisolone). 4) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 5) Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 6) Patients with the past history of severe allergic reactions. 7) Patients who had enrolled in another trial within 6 months or who are treating in another trial. 8) Patients who had received any peptides using this study. 9) Patients who are difficult to participate in this trial because of psychiatric symptoms. 10) Patients who are judged inappropriate for entry to this clinical trial by doctors.

发起方

Kurume University Cancer Vaccine Center